Selected research
Industry Research
Pharma Ophthalmic Industry Research Report 2026
Market perspective
The global Pharma Ophthalmic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pharma Ophthalmic is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pharma Ophthalmic is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pharma Ophthalmic is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pharma Ophthalmic include Akorn, Allergan, Regeneron, Senju, Valeant, Bayer, Santen, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pharma Ophthalmic market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharma Ophthalmic Market by Company
Akorn
Allergan
Regeneron
Senju
Valeant
Bayer
Santen
Pfizer
Roche
Novartis
Pharma Ophthalmic Segment by Type
Retinal disorders drugs
Glaucoma drugs
Other ophthalmic drugs
Allergic, inflammatory and infective drugs
Dry eye drugs
Pharma Ophthalmic Segment by Application
Dry eye syndrome
Other ophthalmic indications
Glaucoma
Retinal diseases
Pharma Ophthalmic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Ophthalmic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharma Ophthalmic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Ophthalmic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pharma Ophthalmic manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pharma Ophthalmic by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pharma Ophthalmic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Retinal disorders drugs
- Glaucoma drugs
- Other ophthalmic drugs
- Allergic, inflammatory and infective drugs
- Dry eye drugs
Applications
- Dry eye syndrome
- Other ophthalmic indications
- Glaucoma
- Retinal diseases
Companies covered
- Akorn
- Allergan
- Regeneron
- Senju
- Valeant
- Bayer
- Santen
- Pfizer
- Roche
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pharma Ophthalmic Market Size (2021-2032)
- 2.2.2 Global Pharma Ophthalmic Sales (2021-2032)
- 2.2.3 Global Pharma Ophthalmic Market Average Price (2021-2032)
- 2.3 Pharma Ophthalmic by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Retinal disorders drugs
- 2.3.3 Glaucoma drugs
- 2.3.4 Other ophthalmic drugs
- 2.3.5 Allergic, inflammatory and infective drugs
- 2.3.6 Dry eye drugs
- 2.4 Pharma Ophthalmic by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Dry eye syndrome
- 2.4.3 Other ophthalmic indications
- 2.4.4 Glaucoma
- 2.4.5 Retinal diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pharma Ophthalmic Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pharma Ophthalmic Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pharma Ophthalmic Revenue of Manufacturers (2021-2026)
- 3.4 Global Pharma Ophthalmic Average Price by Manufacturers (2021-2026)
- 3.5 Global Pharma Ophthalmic Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pharma Ophthalmic, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pharma Ophthalmic, Product Type & Application
- 3.8 Global Manufacturers of Pharma Ophthalmic, Established Date
- 3.9 Global Pharma Ophthalmic Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Akorn
- 4.1.1 Akorn Company Information
- 4.1.2 Akorn Business Overview
- 4.1.3 Akorn Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Akorn Pharma Ophthalmic Product Portfolio
- 4.1.5 Akorn Recent Developments
- 4.2 Allergan
- 4.2.1 Allergan Company Information
- 4.2.2 Allergan Business Overview
- 4.2.3 Allergan Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Allergan Pharma Ophthalmic Product Portfolio
- 4.2.5 Allergan Recent Developments
- 4.3 Regeneron
- 4.3.1 Regeneron Company Information
- 4.3.2 Regeneron Business Overview
- 4.3.3 Regeneron Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Regeneron Pharma Ophthalmic Product Portfolio
- 4.3.5 Regeneron Recent Developments
- 4.4 Senju
- 4.4.1 Senju Company Information
- 4.4.2 Senju Business Overview
- 4.4.3 Senju Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Senju Pharma Ophthalmic Product Portfolio
- 4.4.5 Senju Recent Developments
- 4.5 Valeant
- 4.5.1 Valeant Company Information
- 4.5.2 Valeant Business Overview
- 4.5.3 Valeant Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Valeant Pharma Ophthalmic Product Portfolio
- 4.5.5 Valeant Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Pharma Ophthalmic Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Santen
- 4.7.1 Santen Company Information
- 4.7.2 Santen Business Overview
- 4.7.3 Santen Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Santen Pharma Ophthalmic Product Portfolio
- 4.7.5 Santen Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Pharma Ophthalmic Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Roche
- 4.9.1 Roche Company Information
- 4.9.2 Roche Business Overview
- 4.9.3 Roche Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Roche Pharma Ophthalmic Product Portfolio
- 4.9.5 Roche Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Pharma Ophthalmic Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Pharma Ophthalmic Product Portfolio
- 4.10.5 Novartis Recent Developments
5 Global Pharma Ophthalmic Market Scenario by Region
- 5.1 Global Pharma Ophthalmic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pharma Ophthalmic Sales by Region: 2021-2032
- 5.2.1 Global Pharma Ophthalmic Sales by Region: 2021-2026
- 5.2.2 Global Pharma Ophthalmic Sales by Region: 2027-2032
- 5.3 Global Pharma Ophthalmic Revenue by Region: 2021-2032
- 5.3.1 Global Pharma Ophthalmic Revenue by Region: 2021-2026
- 5.3.2 Global Pharma Ophthalmic Revenue by Region: 2027-2032
- 5.4 North America Pharma Ophthalmic Market Facts & Figures by Country
- 5.4.1 North America Pharma Ophthalmic Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pharma Ophthalmic Sales by Country (2021-2032)
- 5.4.3 North America Pharma Ophthalmic Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pharma Ophthalmic Market Facts & Figures by Country
- 5.5.1 Europe Pharma Ophthalmic Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pharma Ophthalmic Sales by Country (2021-2032)
- 5.5.3 Europe Pharma Ophthalmic Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pharma Ophthalmic Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pharma Ophthalmic Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pharma Ophthalmic Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pharma Ophthalmic Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pharma Ophthalmic Market Facts & Figures by Country
- 5.7.1 South America Pharma Ophthalmic Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pharma Ophthalmic Sales by Country (2021-2032)
- 5.7.3 South America Pharma Ophthalmic Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pharma Ophthalmic Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pharma Ophthalmic Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pharma Ophthalmic Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pharma Ophthalmic Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pharma Ophthalmic Sales by Type (2021-2032)
- 6.1.1 Global Pharma Ophthalmic Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Pharma Ophthalmic Sales Market Share by Type (2021-2032)
- 6.2 Global Pharma Ophthalmic Revenue by Type (2021-2032)
- 6.2.1 Global Pharma Ophthalmic Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pharma Ophthalmic Revenue Market Share by Type (2021-2032)
- 6.3 Global Pharma Ophthalmic Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pharma Ophthalmic Sales by Application (2021-2032)
- 7.1.1 Global Pharma Ophthalmic Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Pharma Ophthalmic Sales Market Share by Application (2021-2032)
- 7.2 Global Pharma Ophthalmic Revenue by Application (2021-2032)
- 7.2.1 Global Pharma Ophthalmic Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pharma Ophthalmic Revenue Market Share by Application (2021-2032)
- 7.3 Global Pharma Ophthalmic Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pharma Ophthalmic Value Chain Analysis
- 8.1.1 Pharma Ophthalmic Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pharma Ophthalmic Production Mode & Process
- 8.2 Pharma Ophthalmic Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pharma Ophthalmic Distributors
- 8.2.3 Pharma Ophthalmic Customers
9 Global Pharma Ophthalmic Analyzing Market Dynamics
- 9.1 Pharma Ophthalmic Industry Trends
- 9.2 Pharma Ophthalmic Industry Drivers
- 9.3 Pharma Ophthalmic Industry Opportunities and Challenges
- 9.4 Pharma Ophthalmic Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst